Is there any domestic product in Seleniso?

Selinexor is an antineoplastic agent and a nuclear export inhibitor. Although the original Seleniso drug has been launched in China and is included in the scope of Class B medical insurance, there is currently no domestic Seleniso sold by relevant pharmaceutical companies in the country. There may be relevant research on domestic drugs. It is believed that in the near future, domestic Seleniso tablets will be put on the market for sale. The indications for which selinesol is currently marketed include the following:

Selinisol in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (R/R MM) in patients who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulators, and an anti-CD38 monoclonal antibody (an FDA-designated orphan drug for the treatment of this cancer); also in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy. The guidelines recommend triple therapy with two novel drugs (immunomodulatory drugs, proteasome inhibitors, or monoclonal antibodies) plus a steroid for the treatment of relapsed or refractory disease. Due to the lack of comparative trials, no preference was given for one option over another.

Selinisol may also be indicated for the treatment of adult patients with unspecified relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), including DLBCL caused by follicular lymphoma, after receiving at least two systemic therapies. Seleniso's accelerated approval for this indication was based on response rate and it was designated as an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of DLBCL.

Seleniso, which is marketed in China, has been included in the Class B medical insurance. Patients who meet its indications can use medical insurance reimbursement to purchase the drug. The market price of each box may be more than more than 20,000 yuan. Patients in need can consult at local hospitals or pharmacies.